scholarly journals Contrast-Enhanced Color Doppler Ultrasonography for Preoperative Evaluation of Sentinel Lymph Node in Breast Cancer Patients

Breast Care ◽  
2015 ◽  
Vol 10 (5) ◽  
pp. 331-335 ◽  
Author(s):  
Dionysios Dellaportas ◽  
Andreas Koureas ◽  
John Contis ◽  
Panagis M. Lykoudis ◽  
Irene Vraka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Cancer Patients ◽  
Doppler Ultrasonography ◽  
Color Doppler ◽  
Color Doppler Ultrasonography ◽  
Contrast Enhanced Ultrasound ◽  
Breast Cancer Patients ◽  
Contrast Enhanced

Background: Sentinel lymph node (SLN) biopsy is the standard of care for breast cancer patients with non-palpable axillary lymph nodes. We evaluated the usefulness of contrast-enhanced ultrasonography in preoperative detection of malignant SLNs. Methods: 50 patients with breast cancer (median age: 60 years) underwent a color power Doppler ultrasonography with intravenous contrast (Sonovue®) preoperatively, and findings suggestive of metastatic disease to the SLN were documented. The final histopathological report and the radiological preoperative record were compared. Finally, the sensitivity, specificity and diagnostic accuracy of this evolving diagnostic modality were calculated. Results: Contrast-enhanced ultrasound scan identified a negative SLN in the axilla of 27 patients and final histopathology was negative for 30 cases in total, so negative predictive value was calculated as 90% and positive predictive value was 75%. Overall sensitivity was 83.33% and specificity was 84.38%. Moreover, the ability of contrast-enhanced ultrasound to differentiate between SLN status was only statistically significantly correlated with the actual final histopathological report (p < 0.001), while successful ultrasound prediction was not correlated with any factor. Conclusions: SLN status can be evaluated preoperatively using contrast-enhanced color Doppler ultrasonography with high accuracy.

scholarly journals The Value of Contrast Enhanced Ultrasound in the Location of Sentinel Lymph Node in Breast Cancer

2018 ◽  
Vol 4 (Supplement 2) ◽  
pp. 34s-34s
Author(s):  
J. Luo ◽  
L. Feng ◽  
C. Wu ◽  
J. Luo ◽  
J. Chen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Cancer Patients ◽  
Ultrasound Contrast Agents ◽  
Blue Dye ◽  
Breast Cancer Patients ◽  
Sentinel Nodes ◽  
Contrast Enhanced ◽  
Detection And Localization

Background: Sentinel lymph node (SLN) location and biopsy was designed to minimize side effects of axillary dissection with equivalent outcomes. Aim: To evaluate the feasibility of periareolar injection of contrast agent SonoVueTM followed by ultrasound (US) for identification and localization of SLN in breast cancer patients with clinically negative node. Methods: From July 2017 through January 2018, 130 women were enrolled in the study. SonoVueTM was injected periareolarly and followed by US to detect enhanced sentinel lymphatic channels (SLCs) and SLNs 1 minute later after massage. The patients were randomly divided into two groups to locate the first enhanced SLN: 1) US-guided marker placing; 2) US-guided nano-carbon (N) injection into SLN. Compare the number of SLNs detect by CEUS with blue dye (B) or N mapping, and the coincidence rate of the first SLN located by CEUS with those traced by the B and N. Lymph nodes that were dark, blue, with marker or clinically positive were considered sentinel nodes and to be biopsied. Results: 121 of 130 patients with breast cancer patients injected with ultrasound contrast agents had detected a total of 254 enhanced SLNs (range 1-5, 2.1 ± 1.05) compared with total of 342 SLNs (range 1-5, 2.83 ± 1.10) mapping with B or N. 42 of 45 first SLNs located with marker matched with first SLNs stained with N (42/45, 93.33%); 70 of 76 first SLNs using N injecting directly guided by CEUS matched with first SLNs stained with B (70/76, 92.1%). In another 9 cases without enhanced SLN, 4 of them didn't stained with N or B, and 5 were stained. The sensitivity of SLNs detection by CEUS was 96.03% (121/126), and the accuracy of locating the first SLN was 92.56% (112/121). Conclusion: CEUS has good accuracy in the detection and localization of SLNs in patients with breast cancer.

scholarly journals The value of contrast‐enhanced ultrasound in determining the location of sentinel lymph nodes in breast cancer

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jun Luo ◽  
Liting Feng ◽  
Qing Zhou ◽  
Qin Chen ◽  
Jinping Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Lymph Nodes ◽  
Lymph Node Biopsy ◽  
Contrast Enhanced Ultrasound ◽  
Breast Cancer Patients ◽  
Identification Rate ◽  
Node Biopsy ◽  
Contrast Enhanced

Abstract Background This study aimed to explore the sentinel lymph node (SLN) identification rate in breast cancer by subcutaneous and intradermal injection of ultrasound contrast agent in the mammary areola region, compared to the results achieved with methylene blue (MB). Methods A total of 390 breast cancer patients with planned sentinel lymph node biopsy from our breast surgery department from July 2017 to February 2019 were enrolled. All patients were subjected to preoperative contrast-enhanced ultrasound (CEUS), that involved an intracutaneous injection of 1 mL ultrasonic contrast agent (UCA) at 3 and 6 o ‘clock, as well as a subcutaneous injection of 1 mL UCA at 9 and 12 o’clock. The enhanced lymph nodes along the enhanced lymphatic vessels from the mammary areola were traced. The number of enhanced lymph nodes were recorded, and an ultrasound-guided injection of 1:10 diluted carbon nanoparticles were used to mark all first site enhanced lymph nodes (i.e., SLNs). An intraoperative dye method (MB) was used to track the SLNs and the results were compared with the CEUS findings. Results Among the 390 cases of breast cancer, enhanced SLNs were observed in 373 patients after an injection of UCA with an identification rate of 95.64 % (373/390), compared to the identification rate of 92.05 % (359/390) using the intraoperative MB. The difference between the two methods was statistically significant (P = 0.016). And among the 390 patients, a total of 808 enhanced lymph nodes were traced by preoperative CEUS, with a median of 2 (1,3). A total of 971 blue-stained lymph nodes were traced using the intraoperative MB, with a median of 2 (2,3), indicating a statistically significant difference (p < 0.001). Conclusions Intradermal and subcutaneous injections of UCA in the mammary areola region may have clinical application value for the identification and localization of SLNs in breast cancer patients. The identification rate is higher than that of blue dye method, which can be used as a new tracer of sentinel lymph node biopsy and complement other staining methods to improve the success rate.

Sign in / Sign up

Export Citation Format

Share Document